Session

Pharmaceutical and Natural Sciences

Description

SARS-CoV-2 belongs the family betacoronavirus in Coronoviridae; it is known to have single strand RNA which is enveloped. The first case is reported late2019 in China. From there it is circulate around the world, causing the COVID-19 pandemic situation with higher fatality rates. At the beginner of April 2021 SARS-CoV-2 has infected more than 130 million people and led to 2.84 million death. There are several strategies for cure of SARS-CoV-2 infection, to date the number of drugs who are used for treatment is increased depends of these drugs are used alone or in combination form. FDA has approved remedesivir who have the ability to neutralized antibodies, although clinical effects were controversial. Here we discuss for development of new strategies for therapeutic reason in patients infected by SARS-CoV-2.

Keywords:

SARS-CoV-2, replication, human proteins, small and large molecules

Proceedings Editor

Edmond Hajrizi

ISBN

978-9951-550-47-5

First Page

1

Last Page

13

Location

UBT Kampus, Lipjan

Start Date

30-10-2021 12:00 AM

End Date

30-10-2021 12:00 AM

DOI

10.33107/ubt-ic.2021.96

Download

Share

COinS
 
Oct 30th, 12:00 AM Oct 30th, 12:00 AM

Anti-SARS-coronavirus treatment based on molecular interaction

UBT Kampus, Lipjan

SARS-CoV-2 belongs the family betacoronavirus in Coronoviridae; it is known to have single strand RNA which is enveloped. The first case is reported late2019 in China. From there it is circulate around the world, causing the COVID-19 pandemic situation with higher fatality rates. At the beginner of April 2021 SARS-CoV-2 has infected more than 130 million people and led to 2.84 million death. There are several strategies for cure of SARS-CoV-2 infection, to date the number of drugs who are used for treatment is increased depends of these drugs are used alone or in combination form. FDA has approved remedesivir who have the ability to neutralized antibodies, although clinical effects were controversial. Here we discuss for development of new strategies for therapeutic reason in patients infected by SARS-CoV-2.